Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia

Leukemia Research

Volumn 31, Issue 11, 2007, Pages 1545-1551

  Schimmel, Kirsten J M ^a   Nijmeijer, Bart A ^a   van Schie, Marianke L J ^a   Falkenburg, J H Frederik ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALL; CPEC; Cyclopentenyl cytosine; Leukemia; NOD scid

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; CYTIDINE TRIPHOSPHATE SYNTHASE; CYTOTOXIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTIDINE; HUMANS; KARYOTYPING; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 34547563011     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.03.022     Document Type: Article

References (20)

1. Faderl S., Jeha S., and Kantarjian H.M. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98 (2003) 1337-1354
2. Van den Berg A.A., Van Lenthe H., Busch S., Van Kuilenburg A.B.P., and Van Gennip A.H. The roles of uridine-cytidine kinase and CTP synthetase in the synthesis of CTP in malignant human T-lymphocytic cells. Leukemia 8 (1994) 1375-1378
3. Ellims P.H., Gan T.E., and Medlye G. Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res 43 (1983) 1432-1435
4. Verschuur A.C., Gennip A.H.V., Leen R., Meinsma R., Voûte P.A., and Kuilenburg A.B.P. In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia. Br J Haematol 110 (2000) 161-169
5. Verschuur A.C., Van Gennip A.H., Leen R., Muller E.J., Elzinga L., Voute P.A., et al. Cyclopentenyl cytosine inhibits cytidine triphosphate sytnhetase activity in paediatric acute non-lymphocytic leukemia: a promising target for chemotherapy. Eur J Cancer 36 (2000) 627-635
6. Marquez V.E., Lim M.I., Treanor S.P., Plowman J., Priest M.A., Markovac A., et al. Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. J Med Chem 31 (1988) 1687-1694
7. Ford Jr. H., Cooney D.A., Ahluwalia G.S., Hao Z., Rommel M.E., Hicks L., et al. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res 51 (1991) 3733-3740
8. Gharehbaghi K., Zhen W., Fritzer-Szekeres M., Szekeres T., and Jayaram H.M. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo. Life Sci 64 (1999) 103-112
9. Politi P.M., Xie F., Dahut W., Ford H., Kelley J.A., Bastian A., et al. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol 36 (1995) 513-523
10. Schimmel K.J.M., Bennink R., Bruin de K., Leen R., Sand C., Hoff van den M.J., et al. Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. Arch Toxicol 79 (2005) 268-276
11. Ford H., Driscoll J.S., Hao Z., Dobyns K.A., Rommel M.A., Stowe E., et al. Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity. Biochem Pharm 49 (1995) 173-180
12. Moyer J.D., Malinowski N.M., Treanor S.P., and Marquez V.E. Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice. Cancer Res 46 (1986) 3325-3329
13. Verschuur A.C., Brinkman J., Gennip A.H.V., Leen R., Vet R., Evers L., et al. Cyclopentenyl cytosine induces apoptosis and increases cytarabine induced apoptosis in a T-lymphoblastic leukemic cell-line. Leuk Res 25 (2001) 891-900
14. Goselink H.M., Damme van J., Hiemstra P.S., Wuyts A., Stolk J., Fibbe W.E., et al. Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase. J Exp Med 184 (1996) 1305-1312
15. Hoorn M.A.W.G.V., Luxemburg-Heijs S.A.P., Bergen C.A.M.V., Bongaerts R., Willemze R., and Falkenburg J.H.F. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. Methods 31 (2003) 113-119
16. Jonker D.M., Visser S.A.G., Graaf van der P.H., Voskuyl R.A., and Danhof M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106 (2005) 1-18
17. Meco D., Colombo T., Ubezio P., Zucchetti M., Zaffaroni M., Riccardi A., et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 52 (2003) 131-138
18. Nijmeijer B.A., Mollevanger P., Zelderen-Bhola S.L., Kluin-Nelemans H.C., Willemze R., and Falkenburg J.H.F. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/scid mice. Exp Hematol 29 (2001) 322-329
19. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58 (2006) 621-681
20. Verschuur A.C., Van Gennip A.H., Leen R., Voute P.A., Brinkman J., and Van Kuilenburg A.B.P. Cyclopentenyl cytosine increases the phoshorylation and incorporation into DNA of 1-beta-d-arabinofuranosyl cytosine in a human T-lymphoblastic cell line. Int J Cancer 98 (2002) 616-623